Virginia Retirement Systems Et Al Viking Therapeutics, Inc. Transaction History

Virginia Retirement Systems Et Al

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 21, 2021	SELL	$5.58 - $7.04 $70,866 - $89,408	-12,700 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$5.19 - $6.73 $143,763 - $186,421	-27,700 Reduced 68.56%	12,700 $76,000
Q1 2021 Apr 30, 2021	SELL	$5.74 - $9.67 $248,542 - $418,711	-43,300 Reduced 51.73%	40,400 $256,000
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $10,600 - $13,420	-2,000 Reduced 2.33%	83,700 $471,000
Q3 2020 Nov 12, 2020	SELL	$5.73 - $8.11 $17,190 - $24,330	-3,000 Reduced 3.38%	85,700 $499,000
Q2 2020 Aug 12, 2020	SELL	$4.35 - $8.08 $73,950 - $137,360	-17,000 Reduced 16.08%	88,700 $640,000
Q1 2020 May 12, 2020	BUY	$3.45 - $7.95 $18,975 - $43,725	5,500 Added 5.49%	105,700 $495,000
Q4 2019 Jan 27, 2020	SELL	$6.38 - $8.73 $16,588 - $22,698	-2,600 Reduced 2.53%	100,200 $804,000
Q3 2019 Oct 22, 2019	SELL	$6.55 - $8.6 $8,515 - $11,180	-1,300 Reduced 1.25%	102,800 $707,000
Q2 2019 Jul 26, 2019	BUY	$7.67 - $10.63 $661,921 - $917,369	86,300 Added 484.83%	104,100 $864,000
Q1 2019 Apr 25, 2019	BUY	$7.58 - $9.94 $134,924 - $176,932	17,800 New	17,800 $177,000

473

65.6M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.09B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

Stay updated on Virginia Retirement Systems Et Al with notifications on news.